Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

Global Medical Genetics is a premier open-access journal dedicated to advancing the field of medical genetics. Published by GEORG THIEME VERLAG KG, this journal has been providing a dynamic platform for disseminating cutting-edge research and clinical findings since its inception in 2020. With the ISSN 2699-9404, it serves as an essential resource for researchers, healthcare professionals, and students who seek to explore the complex interplay between genetics and medicine. The journal aims to foster collaboration and innovation in the genetics community, addressing a diverse range of topics from genetic disorders to the application of genomics in personalized medicine. By providing open access to its content, Global Medical Genetics enhances knowledge sharing and accelerates advancements in healthcare, making it a vital asset for anyone invested in the future of genetics.

Cancer Genetics is an esteemed peer-reviewed journal dedicated to advancing the field of cancer research through the lens of genetics. Published by Elsevier Science Inc and available in both print (ISSN: 2210-7762) and online (E-ISSN: 2210-7770), this journal aims to provide a platform for the dissemination of high-quality studies that unravel the genetic underpinnings of cancer. Since its inception in 2011, Cancer Genetics has become a significant resource for researchers, professionals, and students with a shared interest in understanding the intricate relationship between genetics and oncogenesis. With an impact factor that reflects its influence, the journal has maintained a Q3 ranking in Cancer Research, Genetics, and Molecular Biology as of 2023, indicating its growing importance in these fields. Additionally, the journal offers open access options to ensure that crucial findings are easily accessible to the global research community. By bridging the gap between genetics and cancer studies, Cancer Genetics plays a pivotal role in fostering innovation and collaboration among scientists and clinicians striving to improve cancer diagnosis and treatment.

CHROMOSOMA is a prestigious journal dedicated to advancing the field of genetics, published by Springer in Germany. With an ISSN of 0009-5915 and an E-ISSN of 1432-0886, this journal has been a cornerstone in the publishing landscape since its inception in 1939, serving as a critical resource for researchers and professionals interested in the intricacies of chromosomal biology. Although it operates on a subscription basis, the journal's rigorous peer-review process ensures the dissemination of high-quality research findings. With a commendable Q2 ranking in both genetic and clinical genetics categories as of 2023, CHROMOSOMA aims to bridge theoretical concepts with practical applications in medicine and biology. Researchers will appreciate its relevance, as indicated by its Scopus ranks and integration of diverse topics ranging from molecular genetics to clinical implications. By fostering collaboration and knowledge-sharing among scholars, CHROMOSOMA continues to shape the future of genetic research.

CHROMOSOME RESEARCH is a prestigious academic journal dedicated to advancing the field of genetics, published by SPRINGER. Operative since 1993, this journal is widely recognized for its contributions to the understanding of chromosomal dynamics, genetic interactions, and molecular biology, maintaining a significant impact factor that places it in the Q2 category within its field as of 2023. Despite being a non-open access publication, CHROMOSOME RESEARCH provides essential insights and peer-reviewed articles that are invaluable to researchers, professionals, and students alike, with continual publication through the convergence years stretching towards 2024. Furthermore, with a Scopus rank of #187 out of 347 in the Genetics category, it resides in the 46th percentile, epitomizing its relevance and scholarly rigor within the scientific community. For those engaged in the intricate study of genetics and chromosomal studies, CHROMOSOME RESEARCH remains a crucial resource for disseminating pivotal research findings and facilitating academic discourse.

LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.

Reproductive Medicine is an esteemed open-access journal published by MDPI, focusing on the latest research and advances in reproductive health, fertility, and assisted reproductive technologies. With its E-ISSN of 2673-3897, the journal aims to provide a platform for researchers, clinicians, and healthcare professionals to disseminate their findings, share innovative practices, and engage in scholarly discourse. Situated in Basel, Switzerland, Reproductive Medicine emphasizes a multidisciplinary approach, exploring biological, clinical, and psychological aspects of reproductive health. Although the journal is in the early stages of establishing metrics such as H-index and Scopus rankings, its open-access model enhances accessibility, allowing for a broad dissemination of knowledge. Committed to fostering advancements in the field, Reproductive Medicine is essential for those seeking to stay at the forefront of reproductive health research.

OPHTHALMIC GENETICS is a distinguished journal published by TAYLOR & FRANCIS INC, specializing in the intersection of genetics and ophthalmology. Established in 1981, the journal has become a vital resource for researchers, clinicians, and students interested in the genetic aspects of eye diseases and disorders. Despite not being an Open Access journal, it maintains a commendable impact within the academic community, as reflected by its Q3 ranking in clinical genetics and Q2 rankings in both ophthalmology and pediatrics in 2023. With a robust focus on clinical applications, OPHTHALMIC GENETICS aims to provide a platform for innovative research and insights that drive advancements in patient care and understanding of genetic conditions affecting vision. The journal's international readership is supported by its timely publication of articles that bridge the gap between genetic research and practical ophthalmological applications.

Cold Spring Harbor Molecular Case Studies is a prestigious journal published by COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT, that has garnered considerable attention in the fields of Biochemistry, Genetics, and Molecular Medicine. With a focus on the intersection of molecular biology and clinical case studies, this journal serves as a key resource for researchers and practitioners seeking to explore novel insights into genetic disorders and biomedical advances. Its impact is underscored by its categorization in Q2 in various disciplines in 2023, reflecting its significance and influence within the academic community. Although currently not labeled as Open Access, Cold Spring Harbor Molecular Case Studies provides a rigorous platform for disseminating high-quality, peer-reviewed research that drives innovation and enhances understanding in these rapidly evolving fields. As a supporter of advancing scientific knowledge, this journal is essential for those dedicated to the exploration of molecular mechanisms and their clinical implications.

CLINICAL DYSMORPHOLOGY, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of anatomy, genetics, and pediatric health, with a significant focus on the study of congenital disorders and their phenotypic manifestations. Established in 1992, this esteemed journal has contributed valuable insights into the understanding of dysmorphic syndromes and their clinical implications, making it an essential resource for researchers, clinicians, and students alike. With an impact factor indicative of its robust scholarly influence, CLINICAL DYSMORPHOLOGY engages a diverse readership through specialized articles, case studies, and reviews that advance the knowledge of genetic conditions and associated anatomical anomalies. Although it operates under a non-open access model, the journal is highly regarded with a 2023 ranking of Q3 in Anatomy and Q4 in several other relevant categories, reflecting its ongoing commitment to quality research in the domain of clinical medicine. Researchers and professionals are encouraged to contribute to and explore the rich content of this journal as it continues to shape the discourse in dysmorphology and related fields until its expected convergence in 2024.